Live tape
Top 8, mentions 7d7,536META2,263 mentions▲ +0.06GOOGL1,511 mentions▲ +0.02NVDA804 mentions▲ +0.09MUSE666 mentions▲ +0.07MSFT604 mentions▲ +0.06SPY572 mentions▲ +0.05QQQ563 mentions▲ +0.08TSLA553 mentions▲ +0.06

Equity · Healthcare

ALKS

Alkermes plc · NasdaqGS

$40.84 −0.39% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 25, 2026
Price · Chart
Our own end-of-day closes 62 sessions
$60 $40 30 Jun 25 Sep

The line runs $52 on 30 June through $40.84 on 25 September, on a scale from $40 to $60. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ALKS over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $52 on 30 June 2026 through $40.84 on 25 September 2026.

Market cap $6.9B
P/E (TTM) 107.5
52-week range $27 – $55
Avg volume 118.4K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 25, 2026

ALKS insider trades

SEC Form 4 · last 90 days · newest reported trade 3 Sep 2026
Open-market buys 0
Open-market sells 8
Net sold $4.24M
Non-trade filings 4
Date Insider Type Shares Value
03 Sep 2026 Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 2,034 $98K
01 Sep 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Sell 9,000 $423K
17 Aug 2026 Nichols Christian Todd SVP, Chief Commercial Officer Sell 7,576 $373K
03 Aug 2026 Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 2,034 $99K
03 Aug 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Sell 9,000 $437K
03 Aug 2026 snyderman nancy lynn MD Director Sell 44,472 $2.24M
06 Jul 2026 Gaffin David Joseph EVP, CLO, Alkermes, Inc. Sell 2,034 $110K
01 Jul 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Sell 9,000 $464K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Sep 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Option exercise 5,000 $123K
03 Aug 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Option exercise 5,000 $122K
03 Aug 2026 snyderman nancy lynn MD Director Option exercise 44,472 $2.08M
01 Jul 2026 Hopkinson Craig C. EVP R&D, Chief Medical Officer Option exercise 5,000 $97K

ALKS reported financials

SEC EDGAR XBRL

ALKS reported revenue of $1.5B for the fiscal year ended 31 Dec 2025. Net income over the same period was $241.7M.

Figure Reported Period
Revenue $1.5B 31 Dec 2025 fiscal year
Net income $241.7M 31 Dec 2025 fiscal year
Diluted EPS $1.43 31 Dec 2025 fiscal year
Total assets $4.4B 30 Jun 2026 at period end
Total equity $1.8B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ALKS earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.00 $496M
31 Mar 2026 Q1 2026 $-0.40 $393M
31 Dec 2025 FY 2025 $1.43 $1.48B
30 Sep 2025 Q3 2025 $0.49 $394M
30 Jun 2025 Q2 2025 $0.52 $391M
31 Mar 2025 Q1 2025 $0.13 $307M
31 Dec 2024 FY 2024 $2.17 $1.56B
30 Sep 2024 Q3 2024 $0.55 $378M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ALKS institutional holders

SEC Form 13F

12 of the 45 institutional funds we track reported a ALKS position for the quarter ended 30 Jun 2026 — a combined $1.2B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 10,012,267 $524.6M
Renaissance Technologies Held (±25%) +4.9% shares 6,460,928 $338.5M
Citadel Advisors Trimmed −26.6% shares 1,645,101 $86.2M
D. E. Shaw & Co. Added +84.7% shares 1,312,031 $68.7M
Two Sigma Investments Added +33.0% shares 1,038,311 $54.4M
Marshall Wace Held (±25%) −2.9% shares 969,954 $50.8M
Fisher Asset Management Held (±25%) +7.3% shares 419,102 $22.0M
Millennium Management New position 319,595 $16.7M
AQR Capital Management Trimmed −44.5% shares 212,968 $11.2M
Balyasny Asset Management Trimmed −75.7% shares 142,366 $7.5M

Showing the 10 largest of 12 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

ALKS fails-to-deliver

SEC CNS data

On 24 Aug 2026, 566 shares of ALKS failed to deliver (about $27K).

Settlement date Shares failed Notional % of shares out
24 Aug 2026 566 $27K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in ALKS

STOCK Act disclosures

The most recent congressional trade disclosed in ALKS is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 30 Jul 2026.

Date Member Type Amount
30 Jul 2026 filed 04 Sep 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $15K–$50K

Source: U.S. House of Representatives financial disclosures